CompletedNot Applicable

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

Japan369 participantsStarted 2011-09

Plain-language summary

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura * Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer Exclusion Criteria: \- H.pylori negative at the time when the triple therapy is started

What they're measuring

Number of Adverse Drug Reactions

Timeframe: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months

Trial details

NCT IDNCT01435525

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2014-03

View on ClinicalTrials.gov More Gastric Ulcer trials